“…Pharmaceuticals are of particular concern due to: 1) relative solubility and high mobility in aqueous environments compared with many other wastewater contaminants; 2) designed high bioactivities and biorecalcitrance; and 3) a wide range of potential ecological endpoints including, toxicity (Han et al, 2006;Oliveira et al, 2015;Quinn et al, 2008;Rosi-Marshall et al, 2013;Xie et al, 2016), endocrine disruption (Kidd et al, 2007;Niemuth et al, 2015;Painter et al, 2009;Vajda et al, 2008), immuno-modulation (Canesi et al, 2007;Gust et al, 2013), antibiotic resistance selection (Haack et al, 2012;Martinez, 2009), as well as cytotoxicity and mutagenesis (Buerge et al, 2006;Johnson et al, 2008). Downstream transport and fate of wastewater contaminants including pharmaceuticals are intensively studied in fluvial systems (see for example, Acuña et al, 2015;Barber et al, 2013;Bradley et al, 2009;Bradley et al, 2007;Bradley and Journey, 2014;Brown et al, 2009;Dong et al, 2015;Fono et al, 2006;Kunkel and Radke, 2011;Lin et al, 2006;Radke et al, 2010;Writer et al, 2012). Surface-water/groundwater contaminant exchange and the fate of surface-water-derived groundwater contaminants, however, are poorly understood in comparison; a critical scientific data gap given the global importance of subsurface freshwater supplies (Oelkers et al, 2011;Schwartz and Ibaraki, 2011;U.S.…”